IRF4 is Correlated with the Conversion to a Th17-Like Phenotype in Regulatory T Cells from the Malignant Pleural Effusion

References

• Koegelenberg C, Shaw JA, Irusen EM, Lee Y. Contemporary best practice in the management of malignant pleural effusion. Ther Adv Respir Dis. 2018;12:1024447158. doi:10.1177/1753466618785098
   Web of Science ®Google Scholar
• Egen JG, Ouyang W, Wu LC. Human anti-tumor immunity: insights from immunotherapy clinical trials. Immunity. 2020;52:36–54. doi:10.1016/j.immuni.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–550. doi:10.1038/s41591-018-0014-x
   PubMed Web of Science ®Google Scholar
• Budna J, Kaczmarek M, Kolecka-Bednarczyk A, et al. Enhanced suppressive activity of regulatory T cells in the microenvironment of malignant pleural effusions. J Immunol Res. 2018;2018:9876014. doi:10.1155/2018/9876014
   PubMed Web of Science ®Google Scholar
• Oliver AJ, Lau P, Unsworth AS, et al. Tissue-dependent tumor microenvironments and their impact on immunotherapy responses. Front Immunol. 2018;9:70. doi:10.3389/fimmu.2018.00070.
   PubMed Web of Science ®Google Scholar
• Sarode P, Schaefer MB, Grimminger F, Seeger W, Savai R. Macrophage and tumor cell cross-talk is fundamental for lung tumor progression: we need to talk. Front Oncol. 2020;10:324. doi:10.3389/fonc.2020.00324
   PubMed Web of Science ®Google Scholar
• Chen YQ, Shi HZ, Qin XJ, et al. CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. Am J Respir Crit Care Med. 2005;172:1434–1439. doi:10.1164/rccm.200504-588OC
   PubMed Web of Science ®Google Scholar
• Ye ZJ, Zhou Q, Zhang JC, et al. CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res. 2011;12:77. doi:10.1186/1465-9921-12-77.
   PubMed Web of Science ®Google Scholar
• Ye ZJ, Zhou Q, Gu YY, et al. Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol. 2010;185:6348–6354. doi:10.4049/jimmunol.1001728
   PubMed Web of Science ®Google Scholar
• Wu XZ, Zhai K, Yi FS, et al. IL-10 promotes malignant pleural effusion in mice by regulating TH1- and TH17-cell differentiation and migration. Eur J Immunol. 2019;49:653–665. doi:10.1002/eji.201847685.
   PubMed Web of Science ®Google Scholar
• Budna J, Spychalski L, Kaczmarek M, et al. Regulatory T cells in malignant pleural effusions subsequent to lung carcinoma and their impact on the course of the disease. Immunobiology. 2017;222:499–505. doi:10.1016/j.imbio.2016.10.017
   PubMed Web of Science ®Google Scholar
• Yang G, Li H, Yao Y, Xu F, Bao Z, Zhou J. Th17 imbalance in malignant pleural effusion partially predicts poor prognosis. Oncol Rep. 2015;33:478–484. doi:10.3892/or.2014.3576.
   PubMed Web of Science ®Google Scholar
• Rocamora-Reverte L, Tuzlak S, von Raffay L, et al. Glucocorticoid Receptor-Deficient Foxp3(+) Regulatory T Cells Fail to Control Experimental Inflammatory Bowel Disease. Front Immunol. 2019;10:472. doi:10.3389/fimmu.2019.00472.
   PubMed Web of Science ®Google Scholar
• Kluger MA, Nosko A, Ramcke T, et al. RORgammat expression in Tregs promotes systemic lupus erythematosus via IL-17 secretion, alteration of Treg phenotype and suppression of Th2 responses. Clin Exp Immunol. 2017;188:63–78. doi:10.1111/cei.1290
   PubMed Web of Science ®Google Scholar
• Ren J, Li B. The Functional Stability of FOXP3 and RORgammat in Treg and Th17 and Their Therapeutic Applications. Adv Protein Chem Struct Biol. 2017;107:155–189. doi:10.1016/bs.apcsb.2016.10.002
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Sido JM, Reyes EE, Kiers V, Cantor H, Kim HJ. Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity. Proc Natl Acad Sci U S A. 2016;113:6248–6253. doi:10.1073/pnas.1604765113
   PubMed Web of Science ®Google Scholar
• Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease. Nat Immunol. 2018;19:665–673. doi:10.1038/s41590-018-0120-4
   PubMed Web of Science ®Google Scholar
• Downs-Canner S, Berkey S, Delgoffe GM, et al. Suppressive IL-17A(+)Foxp3(+) and ex-Th17 IL-17A(neg)Foxp3(+) Treg cells are a source of tumour-associated Treg cells. Nat Commun. 2017;8:14649. doi:10.1038/ncomms14649.
   PubMed Web of Science ®Google Scholar
• Yu WQ, Ji NF, Gu CJ, et al. Downregulation of miR-4772-3p promotes enhanced regulatory T cell capacity in malignant pleural effusion by elevating Helios levels. Chin Med J. 2019;132:2705–2715. doi:10.1097/CM9.0000000000000517.
   PubMed Web of Science ®Google Scholar
• Thornton AM, Lu J, Korty PE, et al. Helios(+) and Helios(-) Treg subpopulations are phenotypically and functionally distinct and express dissimilar TCR repertoires. Eur J Immunol. 2019;49:398–412. doi:10.1002/eji.201847935
   PubMed Web of Science ®Google Scholar
• Sugita K, Hanakawa S, Honda T, et al. Generation of Helios reporter mice and an evaluation of the suppressive capacity of Helios(+) regulatory T cells in vitro. Exp Dermatol. 2015;24:554–556. doi:10.1111/exd.12711
   PubMed Web of Science ®Google Scholar
• Seng A, Krausz KL, Pei D, et al. Coexpression of FOXP3 and a Helios isoform enhances the effectiveness of human engineered regulatory T cells. Blood Adv. 2020;4:1325–1339. doi:10.1182/bloodadvances
   PubMed Web of Science ®Google Scholar
• Kim HJ, Barnitz RA, Kreslavsky T, et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science. 2015;350:334–339. doi:10.1126/science.aad0616
   PubMed Web of Science ®Google Scholar
• Khaitan A, Kravietz A, Mwamzuka M, et al. FOXP3+Helios+ Regulatory T Cells, Immune Activation, and Advancing Disease in HIV-Infected Children. J Acquir Immune Defic Syndr. 2016;72:474–484. doi:10.1097/QAI.0000000000001000
   PubMed Web of Science ®Google Scholar
• Syed KA, Toor SM, El SH, Ali BR, Elkord E. Intratumoral FoxP3(+)Helios(+) Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. Front Immunol. 2017;8:619. doi:10.3389/fimmu.2017.00619
   PubMed Web of Science ®Google Scholar
• Toor SM, Murshed K, Al-Dhaheri M, Khawar M, Abu NM, Elkord E. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4(+) T Cell Subsets in Colorectal Cancer Patients. Front Immunol. 2019;10:2936. doi:10.3389/fimmu.2019.02936
   PubMed Web of Science ®Google Scholar
• Long Y, Zhao X, Xia C, Liu X, Fan C, Liu C. Infection of Epstein-Barr Virus is Associated with the Decrease of Helios(+)FoxP3(+)Regulatory T Cells in Active Ulcerative Colitis Patients. Immunol Invest. 2021;50(1):23–36. doi:10.1080/08820139.2020.1723021
   PubMed Web of Science ®Google Scholar
• Trojan K, Zhu L, Aly M, et al. Association of peripheral NK cell counts with Helios(+) IFN-gamma(-) Tregs in patients with good long-term renal allograft function. Clin Exp Immunol. 2017;188:467–479. doi:10.1111/cei.12945
   PubMed Web of Science ®Google Scholar
• Li X, Li D, Huang X, et al. Helios expression in regulatory T cells promotes immunosuppression, angiogenesis and the growth of leukemia cells in pediatric acute lymphoblastic leukemia. Leuk Res. 2018;67:60–66. doi:10.1016/j.leukres.2018.02.007.
   PubMed Web of Science ®Google Scholar
• Syed KA, Toor SM, El SH, et al. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget. 2017;8:33159–33171. doi:10.18632/oncotarget.16565
   PubMedGoogle Scholar
• Timperi E, Pacella I, Schinzari V, et al. Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer. Oncoimmunology. 2016;5:e1175800. doi:10.1080/2162402X.2016.1175800.
   PubMed Web of Science ®Google Scholar
• Kovacsovics-Bankowski M, Chisholm L, Vercellini J, et al. Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. J Immunother Cancer. 2014;2:38. doi:10.1186/s40425-014-0038-9.
   PubMedGoogle Scholar
• Phillips JD, Knab LM, Blatner NR, et al. Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer. Cancer Immunol Immunother. 2015;64:1185–1191. doi:10.1007/s00262-015-1725-1.
   PubMed Web of Science ®Google Scholar
• Chellappa S, Hugenschmidt H, Hagness M, et al. Regulatory T cells that co-express RORgammat and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer. Oncoimmunology. 2016;5:e1102828. doi:10.1080/2162402X.2015.1102828.
   PubMed Web of Science ®Google Scholar
• Blatner NR, Mulcahy MF, Dennis KL, et al. Expression of RORgammat marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med. 2012;4:159r–164r. doi:10.1126/scitranslmed.3004566.
   Web of Science ®Google Scholar
• Wu J, Zhang H, Shi X, et al. Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4(+) T Cell Dysfunction. Immunity. 2017;47:1114–1128. doi:10.1016/j.immuni.2017.11.003.
   PubMed Web of Science ®Google Scholar
• Biswas PS, Bhagat G, Pernis AB. IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis? Immunol Rev. 2010;233:79–96.
   PubMed Web of Science ®Google Scholar
• Man K, Gabriel SS, Liao Y, et al. Transcription Factor IRF4 Promotes CD8(+) T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection. Immunity. 2017;47:1129–1141. doi:10.1016/j.immuni.2017.11.02.
   PubMed Web of Science ®Google Scholar
• Nam S, Lim JS. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development. Arch Pharm Res. 2016;39:1548–1555. doi:10.1007/s12272-016-0854-1
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454:226–231. doi:10.1038/nature07064.
   PubMed Web of Science ®Google Scholar
• Koizumi SI, Sasaki D, Hsieh TH, et al. JunB regulates homeostasis and suppressive functions of effector regulatory T cells. Nat Commun. 2018;9:5344. doi:10.1038/s41467-018-07735-4
   PubMed Web of Science ®Google Scholar
• Alvisi G, Brummelman J, Puccio S, et al. IRF4 instructs effector Treg differentiation and immune suppression in human cancer. J Clin Invest. 2020;130:3137–3150. doi:10.1172/JCI130426
   PubMed Web of Science ®Google Scholar
• Tang M, Cheng L, Li F, et al. Transcription Factor IRF4 Dysfunction Affects the Immunosuppressive Function of Treg Cells in Patients with Primary Immune Thrombocytopenia. Biomed Res Int. 2019;2019:1050285. doi:10.1155/2019/105028
   PubMed Web of Science ®Google Scholar
• Zheng Y, Chaudhry A, Kas A, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature. 2009;458:351–356. doi:10.1038/nature07674.
   PubMed Web of Science ®Google Scholar
• Vasanthakumar A, Moro K, Xin A, et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol. 2015;16:276–285. doi:10.1038/ni.3085
   PubMed Web of Science ®Google Scholar